Final Glance: Biotechnology companies
AP - Wed Aug 27, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Why Amgen (AMGN) Stock Hit a One-Year High Today
at The Street - Wed Aug 27, 9:32AM CDT
Amgen (AMGN) hit a 52-week high of $137.99 on Wednesday after the Food and Drug Administration granted priority review for the company's prospective chronic heart failure treatment drug ivabradine.
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
PR Newswire - Wed Aug 27, 8:15AM CDT
Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 million people in the U.S.2,3
7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 26, 8:56PM CDT
Regeneron Pharmaceuticals held a conference call earlier this month to highlight its second-quarter earnings and give investors some insight into the biotech's prospects for the rest of the year. Here are seven things management wants you to know....
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.
HCP Boasts Of 29 Years Of Dividend Increases
at Investor's Business Daily - Tue Aug 26, 4:57PM CDT
HCP (HCP) is a real estate investment trust that invests in four health-care sectors: senior housing; post-acute/skilled nursing facilities; life sciences; and medical offices and hospitals. The company manages, acquires, develops and sells...
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
Midday Glance: Biotechnology companies
AP - Tue Aug 26, 12:31PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
17.2% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 26, 11:04AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 17.16% as of today's recent price of $136.43.
3 Reasons Amgen Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 8:43AM CDT
Years of patience are finally paying off for Amgen shareholders, whose shares jump by more than 160% over the past three years. AMGN data by YCharts Amgen's shares have rallied on the prospect of delivering late-stage data on 10 new...
3 Reasons Celgene Corporation's Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 7:49AM CDT
If you've been a long-term shareholder in Celgene stock you have very little to complain about. The company's core drug, Revlimid, a treatment for blood-borne cancers, has grown into what's expected to be a $5 billion blockbuster this year, and...
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.
Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.
Amgen Set to Possibly Pullback After Yesterday's Rally of 1.48%
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell
PR Newswire - Mon Aug 25, 3:15PM CDT
Western Digital Corp. (NASDAQ: WDC) today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company. He is being succeeded by Olivier Leonetti, 50, who has served as vice president, finance at Amgen Inc. from 2011, after having previously spent 14 years in global finance leadership positions at Dell Inc. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8, 2014.